CN107474136B - 增强激动型抗体活性的抗体重链恒定区序列 - Google Patents

增强激动型抗体活性的抗体重链恒定区序列 Download PDF

Info

Publication number
CN107474136B
CN107474136B CN201710429281.6A CN201710429281A CN107474136B CN 107474136 B CN107474136 B CN 107474136B CN 201710429281 A CN201710429281 A CN 201710429281A CN 107474136 B CN107474136 B CN 107474136B
Authority
CN
China
Prior art keywords
ser
val
thr
pro
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710429281.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107474136A (zh
Inventor
李福彬
刘小波
张燕
赵英杰
石欢
张慧慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jiao Tong University
Original Assignee
Shanghai Jiao Tong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jiao Tong University filed Critical Shanghai Jiao Tong University
Priority to CN202210729123.3A priority Critical patent/CN115304669A/zh
Publication of CN107474136A publication Critical patent/CN107474136A/zh
Application granted granted Critical
Publication of CN107474136B publication Critical patent/CN107474136B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201710429281.6A 2016-06-08 2017-06-08 增强激动型抗体活性的抗体重链恒定区序列 Active CN107474136B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210729123.3A CN115304669A (zh) 2016-06-08 2017-06-08 增强激动型抗体活性的抗体重链恒定区序列

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610404956 2016-06-08
CN2016104049567 2016-06-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210729123.3A Division CN115304669A (zh) 2016-06-08 2017-06-08 增强激动型抗体活性的抗体重链恒定区序列

Publications (2)

Publication Number Publication Date
CN107474136A CN107474136A (zh) 2017-12-15
CN107474136B true CN107474136B (zh) 2023-03-07

Family

ID=60578403

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710429281.6A Active CN107474136B (zh) 2016-06-08 2017-06-08 增强激动型抗体活性的抗体重链恒定区序列
CN202210729123.3A Pending CN115304669A (zh) 2016-06-08 2017-06-08 增强激动型抗体活性的抗体重链恒定区序列

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210729123.3A Pending CN115304669A (zh) 2016-06-08 2017-06-08 增强激动型抗体活性的抗体重链恒定区序列

Country Status (5)

Country Link
US (1) US12145993B2 (enExample)
EP (1) EP3470424B1 (enExample)
JP (3) JP2019528082A (enExample)
CN (2) CN107474136B (enExample)
WO (1) WO2017211321A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240110000A (ko) 2015-06-30 2024-07-12 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 Btla 융합 단백질 작용제 및 이의 용도
WO2017211321A1 (zh) * 2016-06-08 2017-12-14 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
CA3085472A1 (en) * 2017-12-19 2019-06-27 The Rockefeller University Human igg fc domain variants with improved effector function
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
KR102813744B1 (ko) * 2017-12-27 2025-05-28 브리스톨-마이어스 스큅 컴퍼니 항-cd40 항체 및 그의 용도
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
KR20210096167A (ko) * 2018-11-28 2021-08-04 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
TWI756621B (zh) * 2019-01-25 2022-03-01 大陸商信達生物製藥（蘇州）有限公司 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
CA3136491A1 (en) * 2019-04-10 2020-10-15 Nankai University Anti-cd40 antibodies and uses thereof
CN110981958B (zh) * 2019-08-23 2020-10-20 四川大学华西医院 一种pd-l1抗体
CN112592404B (zh) * 2019-09-20 2023-07-25 上海交通大学医学院 抗体活性改造及其筛选方法
CN110862455B (zh) * 2019-12-03 2021-12-21 源道隆（苏州）医学科技有限公司 可结合cd47的多肽及其应用
AU2020398327A1 (en) 2019-12-03 2022-07-14 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
BR112022010757A2 (pt) * 2019-12-03 2022-08-16 Shanghai Jiao Tong Univ School Of Medicine Região de anticorpo fc com afinidade de ligação aumentada para fc-gama-riib.
LT4157876T (lt) 2020-05-26 2024-10-25 Boehringer Ingelheim International Gmbh Anti-pd-1 antikūnai
CN114591428B (zh) * 2020-12-04 2024-05-28 上海交通大学医学院 抗Dsg1抗体及其应用
KR102671409B1 (ko) * 2021-03-02 2024-05-31 진화섭 Cd30을 발현하는 세포에 독성을 나타내는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물
KR20250108092A (ko) * 2024-01-02 2025-07-15 젬파마테크 컴퍼니 리미티드 인간화 항체를 생성하는 동물 모델 및 그 제작 방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060093600A1 (en) * 2001-11-09 2006-05-04 Abgenix, Inc. Antibodies to CD40
WO2015070972A1 (en) * 2013-11-12 2015-05-21 Atlab Pharma Human igg1 derived antibody with pro-apoptotic activity
CN104955844A (zh) * 2013-02-01 2015-09-30 瑞泽恩制药公司 包含嵌合恒定结构域的抗体
WO2015184099A1 (en) * 2014-05-28 2015-12-03 4-Antibody Ag Anti-gitr antibodies and methods of use thereof
WO2016081746A2 (en) * 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
BRPI0510674A (pt) 2004-07-15 2007-12-26 Xencor Inc variantes fc otimizadas
MX2007001559A (es) * 2004-08-03 2007-04-10 Transtech Pharma Inc Proteinas de fusion de receptor para productos finales glicados avanzados y metodos de uso.
WO2007046834A2 (en) * 2004-12-22 2007-04-26 Centocor, Inc. Glp-1 agonists, compositions, methods and uses
WO2007067828A2 (en) * 2005-10-24 2007-06-14 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
JP5694921B2 (ja) * 2009-04-20 2015-04-01 協和発酵キリン株式会社 アミノ酸変異が導入されたＩｇＧ２を有する抗体
CA2822366A1 (en) 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
EP3604330A1 (en) * 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
EP2537864B1 (en) * 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
EP2762493B1 (en) * 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
KR102475951B1 (ko) * 2012-02-24 2022-12-08 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자
KR20150013503A (ko) * 2012-05-11 2015-02-05 머크 샤프 앤드 돔 코포레이션 표면 앵커링된 경쇄 미끼 항체 디스플레이 시스템
TWI855488B (zh) * 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
EP2914627B1 (en) 2012-10-30 2021-04-07 Apexigen, Inc. Anti-cd40 antibodies and methods of use
KR20160006168A (ko) * 2013-03-18 2016-01-18 바이오서오엑스 프로덕스 비.브이. 인간화 항-cd134(ox40) 항체 및 이의 용도
JOP20200096A1 (ar) * 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015248785A1 (en) * 2014-04-16 2016-11-24 Ucb Biopharma Sprl Multimeric Fc proteins
US20170196971A1 (en) * 2014-06-05 2017-07-13 The Board Of Trustees Of The University Of Arkansas Antibody guided vaccines and methods of use for generation of rapid mature immune responses
DK3221363T3 (da) * 2014-11-21 2020-08-10 Bristol Myers Squibb Co Antistoffer mod cd73 og anvendelser deraf
BR112018010172A2 (pt) * 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
WO2017211321A1 (zh) * 2016-06-08 2017-12-14 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
CN108623686A (zh) 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
BR112022010757A2 (pt) * 2019-12-03 2022-08-16 Shanghai Jiao Tong Univ School Of Medicine Região de anticorpo fc com afinidade de ligação aumentada para fc-gama-riib.
CN115461122A (zh) * 2020-05-01 2022-12-09 博尔特生物治疗药物有限公司 抗dectin-2抗体
CN114106174A (zh) * 2020-08-27 2022-03-01 苏州景涞医疗科技有限公司 低毒性抗ox40抗体、其药物组合物及应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060093600A1 (en) * 2001-11-09 2006-05-04 Abgenix, Inc. Antibodies to CD40
CN104955844A (zh) * 2013-02-01 2015-09-30 瑞泽恩制药公司 包含嵌合恒定结构域的抗体
WO2015070972A1 (en) * 2013-11-12 2015-05-21 Atlab Pharma Human igg1 derived antibody with pro-apoptotic activity
WO2015184099A1 (en) * 2014-05-28 2015-12-03 4-Antibody Ag Anti-gitr antibodies and methods of use thereof
WO2016081746A2 (en) * 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131);Mimoto，F.等;《Protein Engineering Design & Selection Peds》;20130605;第26卷(第10期);第589-598页 *
Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies;Chu S.Y.等;《Molecular Immunology》;20080808;第45卷(第15期);第3926-3933页 *
Optimization of Fc-mediated effector functions of monoclonal antibodies;Strohl W R.等;《Current Opinion in Biotechnology》;20091104;第20卷(第6期);第685-691页 *
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement;Rony Dahan等;《Cancer Cell》;20160613;第29卷(第6期);第820-831页 *

Also Published As

Publication number Publication date
JP2019528082A (ja) 2019-10-10
WO2017211321A1 (zh) 2017-12-14
JP2021143186A (ja) 2021-09-24
CN107474136A (zh) 2017-12-15
EP3470424A4 (en) 2020-03-04
US12145993B2 (en) 2024-11-19
EP3470424B1 (en) 2025-04-23
EP3470424A1 (en) 2019-04-17
EP3470424C0 (en) 2025-04-23
CN115304669A (zh) 2022-11-08
US20190263918A1 (en) 2019-08-29
JP2024112978A (ja) 2024-08-21

Similar Documents

Publication Publication Date Title
CN107474136B (zh) 增强激动型抗体活性的抗体重链恒定区序列
AU2021200972B2 (en) MULTISPECIFIC NKp46 BINDING PROTEINS
CN113557245B (zh) 人源化的抗人pd-1抗体
US10233258B2 (en) Bispecific binding proteins that bind CD40 and mesothelin
JP7027401B2 (ja) Ｔｉｍ３に対する抗体およびその使用
JP7115758B2 (ja) Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ
CN108738324A (zh) 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
EP3313881A1 (en) Multispecific nk engager proteins
CN113574067A (zh) 双功能抗PD-1/SIRPα分子
US20190322767A1 (en) Heterodimeric antigen binding proteins
WO2021110110A1 (zh) FcγRIIB亲和力增强的抗体Fc区
JP2024544531A (ja) 位置４２９に変異を有するｆｃ領域成分を含む免疫療法タンパク質
EP3091031A1 (en) Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
HK40074321B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20171215

Assignee: Suzhou Jinglian Medical Technology Co.,Ltd.

Assignor: SHANGHAI JIAO TONG University SCHOOL OF MEDICINE

Contract record no.: X2019310000005

Denomination of invention: An antibody heavy chain constant region sequence enhancing activity of an agonistic antibody

License type: Exclusive License

Record date: 20190820

GR01 Patent grant
GR01 Patent grant